Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Wyeth Research, AEterna Laboratories, and Celegne are all launching second-line therapies in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) that will expand the renal cell carcinoma (RCC) drug market. Antigenics will launch a first-line treatment in the seven major markets by 2008. The introduction of these new therapies is expected to offer better toxicity profiles and greater survival benefit for stage IV RCC, according to a new Pharmacor study from Decision Resources entitled Renal Cell Carcinoma.

"We expect agents from Wyeth, AEterna, and Celegene to launch in 2005/2006 and offer alternatives to conventional second-line treatments, with equal or better toxicity profiles," said Mohamed Muhsin, analyst at Decision Resources. "AEterna's drug, Neovastat, and Wyeth's drug, CCI-779, along with Antigenics' Oncophage will penetrate the first-line market in the second half our study period between 2008 and 2012."

Disease Background -- Renal Cell Carcinoma

Renal cell carcinoma is a specific type of kidney cancer that originates in the renal tubules. RCC accounts for 85% of all kidney cancers: approximately 25,000 incident cases are diagnosed each year in the United States, where RCC accounts for 3% of all cancer cases and approximately 1.5% of cancer deaths.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Renal Cell Carcinoma is an Onkos study.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Trouble Ahead for Big Pharma -- Recent Report Warns Large Pharmaceutical Companies to Evolve or Die

View Now